Evaluating long-term outcomes for small non-functional pancreatic tumors
Long-term Prognosis Comparison Between Parenchyma-sparing and Oncologic Resections for Non-functional Neuroendocrine Tumors of the Pancreatic Body and Tail ≤ 3cm: a Real-world Data Study
This study looks at how different types of surgery for small, non-functional pancreatic tumors affect long-term health and quality of life for patients.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Locations | 1 site (Shanghai, Shanghai) |
| Trial ID | NCT05907824 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the malignant potential of non-functional neuroendocrine tumors located in the body and tail of the pancreas that are 3 cm or smaller. By collecting real-world data from major pancreatic surgery centers across the country, the study will evaluate the effectiveness of parenchyma-sparing resection versus oncologic resection. The research will also include a histopathological review and follow-up on long-term prognosis and quality of life for patients. The findings may help clarify surgical management guidelines for these tumors.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with non-functional neuroendocrine tumors of the pancreatic body and tail that are 3 cm or smaller.
Not a fit: Patients with liver or distant metastasis, concomitant malignancies, or those with multifocal or recurrent disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved surgical management and outcomes for patients with small non-functional pancreatic tumors.
How similar studies have performed: Previous studies have shown promising results for similar approaches, indicating that parenchyma-sparing techniques can yield favorable outcomes compared to traditional oncologic resections.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-functional neuroendocrine tumors of the pancreatic body and tail ≤ 3 cm. Exclusion Criteria: * Presence of liver or distant metastasis. * Presence of concomitant malignancy. * Multifocal or recurrent disease. * Presence of hereditary syndrome (MEN1, VHL, NF). * Presence of symptoms (specific symptoms of clinical syndromes suspected to be related to excessive secretion of bioactive compounds). * History of preoperative antitumor therapy. * Loss to follow-up.
Where this trial is running
Shanghai, Shanghai
- Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center — Shanghai, Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Xianjun Yu, MD, PhD — Fudan University
- Study coordinator: Xianjun Yu, MD, PhD
- Email: yuxianjun@fudanpci.org
- Phone: +86-13801669875
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.